Morgan Stanley Cor Medix Inc. Transaction History

Morgan Stanley

$1.59 Trillion
Q3 2025

A detailed history of Morgan Stanley transactions in Cor Medix Inc. stock. As of the latest transaction made, Morgan Stanley holds 843,571 shares of CRMD stock, worth $9.57 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

843,571

Previous 767,253 9.95%

Holding current value

$9.57 Million

Previous $9.45 Million 6.82%

% of portfolio

0.0%

Previous 0.0%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	BUY	$10.07 - $14.83 $768,522 - $1.13 Million	76,318 Added 9.95%	843,571 $10.1 Million
Q2 2025 Aug 15, 2025	BUY	$5.86 - $16.56 $372,186 - $1.05 Million	63,513 Added 9.03%	767,253 $9.45 Million
Q1 2025 May 15, 2025	BUY	$6.16 - $12.57 $1.88 Million - $3.83 Million	304,891 Added 76.44%	703,740 $4.34 Million
Q4 2024 Feb 14, 2025	BUY	$8.1 - $13.59 $457,350 - $767,332	56,463 Added 16.49%	398,849 $3.23 Million
Q3 2024 May 14, 2025	BUY	$3.64 - $8.23 $258,159 - $583,696	70,923 Added 26.13%	342,386 $2.77 Million

Q3 2024 Nov 14, 2024	BUY	$3.64 - $8.23 $258,159 - $583,696	70,923 Added 26.13%	342,386 $2.77 Million
Q2 2024 May 14, 2025	SELL	$4.08 - $6.39 $519,734 - $813,996	-127,386 Reduced 31.94%	271,463 $1.18 Million
Q2 2024 Oct 17, 2024	BUY	$4.08 - $6.39 $308,080 - $482,508	75,510 Added 38.53%	271,463 $1.18 Million
Q2 2024 Aug 14, 2024	BUY	$4.08 - $6.39 $308,080 - $482,508	75,510 Added 38.53%	271,463 $1.18 Million
Q1 2024 Oct 17, 2024	SELL	$2.94 - $4.24 $221,999 - $320,162	-75,510 Reduced 27.82%	195,953 $830,000
Q1 2024 Aug 16, 2024	SELL	$2.94 - $4.24 $161,758 - $233,284	-55,020 Reduced 21.92%	195,953 $830,000
Q1 2024 May 15, 2024	SELL	$2.94 - $4.24 $161,758 - $233,284	-55,020 Reduced 21.92%	195,953 $830,000
Q4 2023 Aug 16, 2024	SELL	$3.0 - $4.01 $61,470 - $82,164	-20,490 Reduced 7.55%	250,973 $943,000
Q4 2023 Feb 13, 2024	BUY	$3.0 - $4.01 $357,816 - $478,280	119,272 Added 90.56%	250,973 $943,000
Q3 2023 Nov 15, 2023	SELL	$3.6 - $4.46 $215,107 - $266,493	-59,752 Reduced 31.21%	131,701 $487,000
Q2 2023 Aug 14, 2023	BUY	$3.94 - $5.8 $275,595 - $405,698	69,948 Added 57.57%	191,453 $758,000
Q1 2023 May 15, 2023	SELL	$3.22 - $4.61 $5,728 - $8,201	-1,779 Reduced 1.44%	121,505 $503,000
Q4 2022 Feb 14, 2023	SELL	$2.81 - $4.45 $4,240 - $6,715	-1,509 Reduced 1.21%	123,284 $520,000
Q3 2022 Nov 14, 2022	SELL	$2.82 - $7.52 $400,690 - $1.07 Million	-142,089 Reduced 53.24%	124,793 $353,000
Q2 2022 Oct 27, 2022	BUY	$2.73 - $5.61 $128,394 - $263,843	47,031 Added 21.39%	266,882 $1.07 Million
Q2 2022 Aug 15, 2022	BUY	$2.73 - $5.61 $128,394 - $263,843	47,031 Added 21.39%	266,882 $1.07 Million
Q1 2022 Oct 27, 2022	SELL	$3.83 - $6.24 $180,128 - $293,473	-47,031 Reduced 17.62%	219,851 $1.21 Million
Q1 2022 May 13, 2022	BUY	$3.83 - $6.24 $258,256 - $420,763	67,430 Added 44.24%	219,851 $1.21 Million
Q4 2021 Feb 14, 2022	SELL	$4.47 - $5.56 $962,243 - $1.2 Million	-215,267 Reduced 58.55%	152,421 $692,000
Q3 2021 Nov 15, 2021	BUY	$4.46 - $7.11 $1.64 Million - $2.61 Million	367,688 New	367,688 $1.71 Million

Others Institutions Holding CRMD

# of Institutions

204

Shares Held

41.2M

Call Options Held

1.33M

Put Options Held

1.3M

View Full List

About CorMedix Inc.

Ticker CRMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,208,200
Market Cap $467M
Description
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath/Neutrolin, a novel anti-infective solution for the reduction and prevention of cathet...

More about CRMD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account